Flonase Sensimist Allergy Relief is a drug owned by Haleon Us Holdings Llc. It is protected by 8 US drug patents filed in 2016. Out of these, 4 drug patents are active and 4 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 15, 2028. Details of Flonase Sensimist Allergy Relief's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US7101866 | Anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) |
Expired
|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8147461 | Fluid dispensing device |
Oct, 2028
(3 years from now) | Active |
| US8347879 | Fluid dispensing device |
Jul, 2028
(3 years from now) | Active |
| US8062264 | Fluid dispensing device |
Apr, 2026
(10 months from now) | Active |
| US8752543 | Fluid dispensing device |
Apr, 2026
(10 months from now) | Active |
| US9320862 | Fluid dispensing device |
Nov, 2024
(6 months ago) |
Expired
|
| US7541350 | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) |
Expired
|
| US6858596 | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Flonase Sensimist Allergy Relief's patents.
Latest Legal Activities on Flonase Sensimist Allergy Relief's Patents
Given below is the list of recent legal activities going on the following patents of Flonase Sensimist Allergy Relief.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 Jun, 2024 | US8347879 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Sep, 2023 | US9320862 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Sep, 2023 | US8147461 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Apr, 2023 | US8062264 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Nov, 2021 | US8752543 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 28 Sep, 2020 | US7541350 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Jun, 2020 | US8347879 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Sep, 2019 | US8147461 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 16 Sep, 2019 | US9320862 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Apr, 2019 | US8062264 |
US patents provide insights into the exclusivity only within the United States, but Flonase Sensimist Allergy Relief is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Flonase Sensimist Allergy Relief's family patents as well as insights into ongoing legal events on those patents.
Flonase Sensimist Allergy Relief's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Flonase Sensimist Allergy Relief's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 15, 2028 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Flonase Sensimist Allergy Relief Generics:
There are no approved generic versions for Flonase Sensimist Allergy Relief as of now.
Alternative Brands for Flonase Sensimist Allergy Relief
Flonase Sensimist Allergy Relief which is used for relieving allergy symptoms such as nasal congestion, runny nose, sneezing, and itchy eyes in individuals aged 12 and up., has several other brand drugs using the same active ingredient (Fluticasone Furoate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Glaxo Grp Ltd |
| |||
| Glaxosmithkline |
|
About Flonase Sensimist Allergy Relief
Flonase Sensimist Allergy Relief is a drug owned by Haleon Us Holdings Llc. It is used for relieving allergy symptoms such as nasal congestion, runny nose, sneezing, and itchy eyes in individuals aged 12 and up. Flonase Sensimist Allergy Relief uses Fluticasone Furoate as an active ingredient. Flonase Sensimist Allergy Relief was launched by Haleon Us Holdings in 2007.
Approval Date:
Flonase Sensimist Allergy Relief was approved by FDA for market use on 27 April, 2007.
Active Ingredient:
Flonase Sensimist Allergy Relief uses Fluticasone Furoate as the active ingredient. Check out other Drugs and Companies using Fluticasone Furoate ingredient
Treatment:
Flonase Sensimist Allergy Relief is used for relieving allergy symptoms such as nasal congestion, runny nose, sneezing, and itchy eyes in individuals aged 12 and up.
Dosage:
Flonase Sensimist Allergy Relief is available in spray, metered form for nasal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.0275MG/SPRAY | SPRAY, METERED | Over the counter | NASAL |